BioSpace News Archive

- BioNJ has released its final speaker roster featuring thought leaders from more than 20 leading biopharmaceutical organizations -- for its Eighth Annual C-Suite Summit, taking place virtually October 30 and November 6 .

Adaptive Biotechnologies Corporation (Nasdaq: ADPT) a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the third quarter ended September 30, 2020 after market close on Tuesday, November 10, 2020. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific T

Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced that it is offering to sell shares of its common stock in an underwritten public offering. The offering is expected to price on or about Wednesday, October 14, 2020. Eton Pharmaceuticals intends to use the net proceeds from the offering primarily for general

Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics, with a focus on oncology and infectious diseases, including COVID-19, today announced the full exercise of the underwriters’ option to purchase an additional 487,500 shares of common stock at the public offering price of $12.00 per share, resulting in add

OpGen’s Acuitas AMR Gene Panel allows testing for a very comprehensive panel of more than 40 diagnostic targets (pathogens and genetic AMR markers) in pure bacterial colonies

Regeneron Pharmaceuticals, Inc. and Sanofi announced that a pivotal Phase 3 trial of Dupixent® met its primary and all key secondary endpoints in children aged 6 to 11 years with uncontrolled moderate-to-severe asthma.

First patient injected in phase I trial evaluating NBTXR3 activated by radiation therapy for patients with pancreatic cancer at The University of Texas MD Anderson Cancer Center in clinical collaboration with Nanobiotix

EUR 15m straight bonds, with no associated dilution, favorable financial conditions in interest rates and no expected transaction fees

AlzeCure Pharma AB announced that the company has received a second abstract approved for poster presentation at the annual Alzheimer’s conference CTAD, Clinical Trials in Alzheimer’s Disease, which this year will be held completely digitally on November 4-7.

University of North Carolina researchers are seeking more than 6,000 participants aged 18 years and over, with first-hand experience of eating disorders to enroll in the world’s largest ever genetic research study into three complex, devastating mental illnesses.